Sk Biopharmaceutica (Korea) Performance
| 326030 Stock | 106,300 1,100 1.05% |
The entity owns a Beta (Systematic Risk) of 0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sk Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sk Biopharmaceutica is expected to be smaller as well. Sk Biopharmaceuticals now owns a risk of 2.93%. Please validate Sk Biopharmaceuticals Co semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to decide if Sk Biopharmaceuticals Co will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Weak
Over the last 90 days Sk Biopharmaceuticals Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Sk Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 59.3 B | |
| Total Cashflows From Investing Activities | 259 B | |
| Free Cash Flow | -98.9 B |
326030 |
Sk Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 10,880,000 in Sk Biopharmaceuticals Co on September 20, 2024 and sell it today you would lose (250,000) from holding Sk Biopharmaceuticals Co or give up 2.3% of portfolio value over 90 days. Sk Biopharmaceuticals Co is generating 0.0044% of daily returns and assumes 2.9349% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than 326030, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sk Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sk Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sk Biopharmaceuticals Co, and traders can use it to determine the average amount a Sk Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 326030 |
Estimated Market Risk
| 2.93 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sk Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sk Biopharmaceutica by adding Sk Biopharmaceutica to a well-diversified portfolio.
Sk Biopharmaceutica Fundamentals Growth
326030 Stock prices reflect investors' perceptions of the future prospects and financial health of Sk Biopharmaceutica, and Sk Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 326030 Stock performance.
| Return On Equity | -0.12 | |||
| Return On Asset | 0.0475 | |||
| Profit Margin | (0.12) % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 78.31 M | |||
| Price To Book | 15.89 X | |||
| Price To Sales | 13.94 X | |||
| Revenue | 418.64 B | |||
| EBITDA | 83.87 B | |||
| Cash Flow From Operations | (92.87 B) | |||
| Earnings Per Share | (117.74) X | |||
| Total Asset | 643.65 B | |||
About Sk Biopharmaceutica Performance
By analyzing Sk Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Sk Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sk Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sk Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Sk Biopharmaceuticals performance evaluation
Checking the ongoing alerts about Sk Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sk Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sk Biopharmaceutica generates negative cash flow from operations | |
| About 64.0% of the company shares are owned by insiders or employees |
- Analyzing Sk Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sk Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Sk Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sk Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sk Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sk Biopharmaceutica's stock. These opinions can provide insight into Sk Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |